QBI Seminar: Deciphering Disease Dynamics, Supporting Drug Discovery, and Empowering Machine Learning Applications with Transformative Proteomic Technologies
Friday, March 13 at 11:00 am
-
12:00 pm
Add to Calendar
2026-03-13 11:00:00
2026-03-13 12:00:00
QBI Seminar: Deciphering Disease Dynamics, Supporting Drug Discovery, and Empowering Machine Learning Applications with Transformative Proteomic Technologies
QBI presents a seminar with:
Jennie Lill, Executive Director and Senior Fellow, Genentech
Dr. Lill has led Proteomics at Genentech for more than 20 years and has personal interests in Immunopeptidomics and chemoproteomics as key tools in drug discovery. She serves on various internal and external committees and has authored over 100 papers in the proteomics arena.
Tess Branon, Principal Scientist and Interactomics Group Lead, Genentech
Dr. Branon codeveloped transformative proximity labeling technologies, such as TurboID, during her training with Alice Ting, enabling rapid, precise, and minimally disruptive mapping of protein interaction networks directly in living systems. As a principal scientist and interactomics group lead at Genentech, she continues to advance interactomic technologies to drive drug discovery and therapeutic research.
Talk Title: Deciphering Disease Dynamics, Supporting Drug Discovery, and Empowering Machine Learning Applications with Transformative Proteomic Technologies
Hosted by Nadia Arang
[email protected]
America/Los_Angeles
public
QBI presents a seminar with:
Jennie Lill, Executive Director and Senior Fellow, Genentech
Dr. Lill has led Proteomics at Genentech for more than 20 years and has personal interests in Immunopeptidomics and chemoproteomics as key tools in drug discovery. She serves on various internal and external committees and has authored over 100 papers in the proteomics arena.
Tess Branon, Principal Scientist and Interactomics Group Lead, Genentech
Dr. Branon codeveloped transformative proximity labeling technologies, such as TurboID, during her training with Alice Ting, enabling rapid, precise, and minimally disruptive mapping of protein interaction networks directly in living systems. As a principal scientist and interactomics group lead at Genentech, she continues to advance interactomic technologies to drive drug discovery and therapeutic research.
Talk Title: Deciphering Disease Dynamics, Supporting Drug Discovery, and Empowering Machine Learning Applications with Transformative Proteomic Technologies
Hosted by Nadia Arang